Cancer clinical trials in the region Normandie

256 currently recruiting clinical trials
Region Normandie
Phase 3 Stomach and esophageal cancer #NCT07431281 #2024-519787-40-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
4 recruiting sites
AstraZeneca
Phase 3 Lung cancer #NCT07431827 #2024-517337-41-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Localized
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery Immunotherapy Chemotherapy
4 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Breast cancer #NCT05696626 #2023-503708-10-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ESR
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded genetic anomalies
Other mutation
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Sermonix Pharmaceuticals Inc.
Phase 3 Rectal cancer #NCT03875781 #2024-510580-28-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Radiotherapy
8 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 3 Colon cancer Rectal cancer Pancreas cancer Stomach and esophageal cancer #NCT06937905 #2024-515948-23-00
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
42 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3 Breast cancer #NCT07060807
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at localized stage
Targeted therapy Hormone therapy
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy Antibody Drug Conjugates (ADC)
4 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Chronic myeloid leukemia (CML) #NCT06423911 #2024-511495-32-00
Required disease stage
Chronic phase
Required genetic anomalies
T315I
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
ATP pocket inhibitor Allosteric inhibitor
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Ascentage Pharma Group Inc.
Phase 3 Chronic myeloid leukemia (CML) #NCT06423911 #2024-511495-32-00
Required disease stage
Chronic phase
Required number of previous lines of therapy
2 3 or more
Required previous treatments
ATP pocket inhibitor Allosteric inhibitor
Excluded genetic anomalies
T315I
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Ascentage Pharma Group Inc.
Phase 3 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Skin cancer #NCT06471465 #2024-510893-25-00
Required previous treatments at localized stage
Radiotherapy
10 recruiting sites
Institut de Cancérologie de l'Ouest
Phase 3 Colon cancer Rectal cancer #NCT06107920 #2024-516456-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy
28 recruiting sites
Hôpital universitaire de Rouen